Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lobe Sciences (LOBE) has entered a joint venture to develop multi-sensory pods for clinical psychedelic use
  • The new psychedelic and virtual experience pod is known as the Krysalis Pod
  • The Krysalis Pod incorporate advanced display technology and bio-monitoring with the goal of improving psychedelic therapy
  • It is expected to offer treatment options for cognitive, psychological, motor and functional impairments across a wide range of clinical health conditions
  • Lobe Sciences is unchanged, with shares trading at C$0.14 at 12:05 pm ET

Lobe Sciences (LOBE) has entered a joint venture to develop multi-sensory pods for clinical psychedelic use.

The joint venture is between Lobe and Virtual Psychedelics Incorporated. The new psychedelic and virtual experience pod is known as the Krysalis Pod.

The companies are also recruiting certain industry-leading pioneers, including Hollywood director Brett Leonard and researcher and USC professor Dr. Skip Rizzo, with respect to joint design, development and commercialization.

Rizzo’s work in clinical virtual reality has been used over the last 20 years for treating veterans with PTSD, assessing children with ADHD, and reducing social anxiety in persons on the autism spectrum. He is the author of over 300 peer-reviewed publications.

The Krysalis Pod will be designed to be powered by a custom tech stack incorporating advanced display technology and state-of-the-art bio-monitoring with the goal of improving psychedelic therapy by optimizing set, setting and the overall experience for clinical and other uses.

The Krysalis Pod is expected to be a headset-free, virtual experience that uses multi-sensory stimulation to create an application that can offer treatment options for cognitive, psychological, motor and functional impairments across a wide range of clinical health conditions.

“Lobe is extremely pleased to partner with industry veterans such as Brett Leonard and Dr. Skip Rizzo, to be at the forefront of psychedelic research, development and treatment. We believe this technology will be able to assist those suffering from depression, PTSD and other mental health issues. The KrysalisTM Pod is being designed as a therapeutic system capable of delivering an easy, immersive media experience, while simultaneously collecting critical biometric data in a safe and monitored environment,” said Lobe Director and CEO Philip Young.

Lobe Sciences is unchanged, with shares trading at C$0.14 at 12:05 pm ET.

More From The Market Herald

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.
Small Pharma - Chief Medical and Scientific Officer, Carol Routledge.

" Small Pharma (TSXV:DMT) granted fast-track designation for DMT-assisted therapy

Small Pharma (DMT) has been granted fast-track designation in the U.K. for DMT-assisted therapy for major depressive disorder.

" Psyched Wellness (CSE:PSYC) shares preliminary data from amanita muscaria mushroom study

Psyched Wellness Ltd. (PSYC) has released its preliminary data revealing a potential new functional property and health benefit of AME-1.
Field Trip Health - President, Hannan Fleiman.

" Field Trip Health (TSX:FTRP) announces three new therapy centers

Field Trip Health (FTRP) is announcing new psychedelic-assisted therapy centers in Seattle, Vancouver and Fredericton.